The c-myc oncogene has been implicated in a wide spectrum of B-cell neoplasias. In normal cells, the level of expression of the c-myc gene correlates with growth status. In the present study, we examined the effect of receptor-mediated inhibition of growth on c-myc expression in a B-cell lymphoma. The murine lymphoma line WEHI 231 has been characterized as an early B cell; it bears surface-bound IgM and has unrearranged c-myc genes. Following treatment of a WEHI 231 culture with anti-mouse Ig antiserum, the cells undergo one round of division and further proliferation is inhibited. We observed that this treatment specifically affected cytoplasmic levels of c-myc mRNA. An initial early increase is followed by a precipitous drop such that by 4 hr (after exposure) the amount of c-myc mRNA is below control values by a factor of -10. The drop in c-myc precedes cessation of DNA synthesis. During the 2-to 4-hr period, c-myc mRNA had a maximal half-life of between 20 and 30 min. In contrast, even 24 hr after anti-Ig exposure, the amounts of most major mRNAs, including ,u heavy chain and actin, were not significantly altered. These results indicate that expression of an unrearranged c-myc gene can be selectively responsive to receptormediated regulatory events.
The response pattern of a B lymphocyte to a particular antigenic signal depends upon many variables, including the stage of differentiation of the cell itself and the presence or absence of ancillary signals such as T-cell factors. The primary B-cell receptor is the specific Ig produced by the cell that becomes integrated within the cell surface membrane (surface-bound Ig, slg). Cross-linking of sIg may result in either stimulation or inhibition of further B-cell development (1) (2) (3) (4) (5) . The interaction of mature B cells with antigen, along with factors derived from helper T cells, triggers the clonal expansion of antigen-specific B cells and the differentiation of those cells to Ig-secreting plasma cells (6, 7) . Conversely, it is postulated that binding of antigen to sIg of developmentally early B cells causes the cessation of cell growth, leading to immunological tolerance (3, 8) . Little is known of the metabolic events that underlie this regulation of B-cell growth and differentiation.
WEHI 231 is a murine lymphoma line that has been characterized as an early B cell on the basis of surface markers and biological properties (9) . Although transformed, these cells remain capable of responding to various immunological stimuli in a manner reminiscent of nontransformed cells, suggesting that they may serve as a useful model for growth control and differentiation of normal B cells. For example, they normally express IgM while secreting only very low amounts of Ig into the medium. Upon stimulation with bacterial lipopolysaccharide, which has been shown to promote B-cell differentiation, they begin secreting pentameric IgM, while levels of surface IgM decrease (10) . Treatment of WEHI 231 with anti-mouse Ig antiserum inhibits proliferation of these cells. The growth inhibition has been shown to be mediated specifically by binding of antibody to surface IgM since it can be effected by a monoclonal anti-mouse IgM antibody, the F(ab')2 portion of this antibody fraction, or the affinity-purified anti-mouse IgM fraction of a rabbit antiserum prepared against mouse Ig (8) . Based on these observations, Boyd and Schrader (8) have proposed that WEHI 231 represents a model system for investigating the mechanism by which interaction with sIg receptor results in inhibition of B-cell growth, and possibly a model system for the study of tolerance.
The proto-oncogene c-myc is a normal cellular gene that has been conserved during evolution (11) and is expressed in all tissue types examined (12) . Perturbations of the c-myc locus have been documented in many B-cell malignancies of human, mouse, and chicken origin. These alterations include the nearby integration of a retrovirus (13) , point mutations (14) , and chromosomal translocations (15) (16) (17) . In addition, cmyc sequences are present in regions of amplified DNA in several human tumors (18) . The c-myc protein has been localized to the nuclear matrix (19) , although its function is not understood. We and others have shown that in nonneoplastically transformed cells the level of c-myc mRNA is low during quiescence and that it increases 10-to 30-fold as the cells begin growing (20, 21) . During differentiation of F9 teratocarcinoma cells to nonproliferating endoderm cells, expression of c-myc message decreases upon terminal differentiation. This evidence suggests that the c-myc gene is involved in some aspect of regulation of cell proliferation.
We have examined the effect of in vitro anti-sIg treatment on gene expression in WEHI 231 cells. Following exposure to anti-mouse Ig antiserum, cells underwent one round of division; growth was arrested by 24 hr. Although levels of most mRNA species remained unchanged during the time period, cytoplasmic c-myc mRNA levels increased quickly and then decreased very suddenly. These results indicate that the c-myc gene is rapidly and selectively controlled after antibody binding to the IgM receptor, and its expression is under both positive and negative regulation.
METHODS
Cell Culture and Antibody Treatment. In these studies we used a variant of WEHI 231 (kindly provided by L. Wysocki), selected for sensitivity to HAT (hypoxanthine/ aminopterin/thymidine) medium. Cells were maintained in Dulbecco's modified Eagle's medium with 20% fetal calf serum supplemented with 0.058% glucose, 0.35% glutamine, nonessential amino acids, and 50 aM 2-mercaptoethanol. Cultures were incubated at 37°C in a 5% CO2 in air mixture. RNA Analysis. Poly(A)-containing cytoplasmic RNA was isolated, denatured, electrophoresed on formaldehyde/agarose gels, transferred to nitrocellulose paper, and hybridized to 32P-labeled probes as described (22) . Relative hybridization intensities were evaluated by scanning densitometry and integration of the peak areas. Quantitation of poly(A) levels was made by using hybridization to [3H]poly(U) (21) . The cmyc sequence probe (kindly provided by R. Taub and P. Leder) was prepared from the c-myc-excluded Ca allele locus of the IgA-producing mouse myeloma S107 and cloned into pBR322 (22) . A genomic clone of the /t heavy chain (CH.7) was kindly supplied by L. Hood. The actin probe was a 1.0-kilobase cDNA clone of rat actin, generously provided by S. Farmer. The c-Ki-ras probe, a subclone of the Kirsten (HiHi3) murine sarcoma virus, was a gift from E. Scolnick.
Cell-free translation of total cytoplasmic RNA in a rabbit reticulocyte lysate, pretreated with micrococcal nuclease, was performed as described (23) . The L-[35S]methionine-labeled polypeptides were reduced with 2-mercaptoethanol, separated on 6-11% linear gradient polyacrylamide/NaDodSO4 gels, and fluorographed as described (23) . Protein Synthesis and Polysome Analysis. At various time points, aliquots of control or antibody-treated cells were removed and incubated with 20 ,tCi of L-[355]methionine (1100 Ci/mmol; Amersham) per ml for 20 min. Following harvesting, cells were resuspended in 50 mM NaCI/50 mM TrisHCl, pH 7.6, and lysed by the addition of Triton X-100 and sodium deoxycholate to 1% final concentrations, and the nuclei were removed by centrifugation. Aliquots were removed and incorporation of radiolabel was measured following precipitation with trichloroacetic acid. Additional samples were analyzed by NaDodSO4/polyacrylamide gel electrophoresis as above.
For analysis of polyribosome structures, control or antibody-treated cultures were chilled rapidly on ice, cells were harvested, cytoplasmic lysates were prepared, and polysomes were separated in 10-40% sucrose (50 mM Tris HCl, pH 7.6/100 mM NaCl/1 mM MgCl2) gradients as described (22) .
RESULTS

Treatment of WEHI 231
Cells with Anti-Ig Antiserum Inhibits Cell Division. To monitor the kinetics of growth inhibition, we evaluated the effect of anti-Ig antiserum treatment Three specific messages were then chosen for further study: c-myc oncogene, ju heavy chain of IgM, and actin. Equal amounts of poly(A)-containing RNA from control and treated cells, isolated at 2.5, 6, and 25 hr, were electrophoresed on a formaldehyde/agarose gel and transferred to cellulose nitrate paper; the resulting blot was hybridized to a 32P-labeled mouse c-myc probe (Fig. 1A) . Parallel control cultures were monitored to evaluate whether the level of cytoplasmic c-myc mRNA would vary during the course of the incubation in the absence of antibody treatment. Levels of cmyc remained essentially unchanged in control cells. In contrast, following exposure to anti-Ig antiserum, the level of cmyc RNA underwent a rapid increase followed by a dramatic decrease to an amount significantly below control levels. Although accurate quantitation by densitometric scanning of data with such vast fluctuations is difficult, an increase over control levels of =10-fold by 21/2 hr and a decrease by a factor of 10 below control values by 24 hr was estimated.
To examine the specificity of the changes, the mRNA levels of ji heavy chain (Fig. 1B) and actin (Fig. 1C) (Fig. 1B) . Presumably, the upper band is for the membrane-associated A heavy chain and the lower band is for the secretory form of this heavy chain polypeptide, as has been shown previously (24) . With antibody treatment, no major changes were observed in the total amounts of heavy chain mRNA; however, a shift was detected in the relative quantities of the two forms. It was not determined whether the cells were triggered to secrete IgM by this treatment. It should be noted that control cells do not secrete significant levels of IgM even though '30% of the mRNA has been apparently processed to the secretory form (unpublished observation). Moreover, antibody treatment did not significantly alter the amounts of poly(A)-containing cytoplasmic messages for actin (Fig. 1C) , as judged by the 6-and 24-hr time points tested.
To further evaluate the effect of anti-Ig treatment on the overall mRNA population, translation in a cell-free system was performed. Equal amounts of total cytoplasmic RNA (10 ug) were used to direct the synthesis of proteins in a rabbit reticulocyte cell-free system, and the [35S]methioninelabeled products were fractionated on a NaDodSO4/polyacrylamide gel (Fig. 2A) . The overall protein profile observed with RNA isolated after 2, 6, or 24 hr of treatment changed very little compared to that obtained with control RNA. (Although not well resolved in this particular gel, it should be noted that one minor band at 28 kDa does appear to be increased in the 24-hr sample.) Thus, though antibody treatment of WEHI 231 cells has little effect on the levels of most cytoplasmic mRNAs, dramatic alterations of expression of c-myc mRNA are observed.
Levels of c-myc mRNA Fluctuate Rapidly, Whereas c-Ki-ras mRNA Levels Remain Essentially Unaltered. To look at the early events in more detail, RNA was isolated after 0, 2, 4, and 6 hr of antibody treatment. Equal amounts of poly(A)-containing RNA were analyzed from each time point (Fig,  3A) . The autoradiograms from this and duplicate blots were scanned to evaluate the quantity of c-myc mRNA in treated cells compared to control cultures. An approximately 5-to 10-fold increase in c-myc RNA levels was observed by 2 hr.
A very rapid decrease in the amount of c-myc mRNA (by a factor of trol, actin levels were again monitored. No significant changes in actin levels were observed over the time course of the experiment (data not shown).
To assess the role of anti-sIg treatment on another oncogene whose expression correlates with cell proliferation, cKi-ras mRNA production was also monitored (Fig. 3B) . In contrast to the c-myc oncogene, expression of the c-Ki-ras oncogene is growth related even in chemically transformed 3T3 cells; c-Ki-ras mRNA levels were observed to increase The pattern of proteins produced by cells after various times of treatment was monitored. Aliquots of cell lysates, normalized for equal cell numbers, were electrophoresed on a NaDodSO4/polyacrylamide gel (Fig. 2B) These results extend previous observations on the growthrelated expression of c-myc mRNA, in which the levels of cmyc message were found to be lower in quiescent BALB/c 3T3 fibroblasts (20, 21) or terminally differentiated endoderm cells than in the actively dividing fibroblasts or F9 stem cells, respectively (21) , and the observation that mitogens that stimulated DNA replication resulted in an early and dramatic increase in c-myc mRNA levels (20) .
During the initial phase of the treatment, an approximate 5-to 10-fold increase in cytoplasmic c-myc mRNA levels occurs. Questions remain as to whether this increase is necessary for the inhibition of growth or results from some form of initial activation of the B cell prior to suppression. The cmyc mRNA appears functional as it has been localized within polyribosome structures (25) . Similar rapid enhancement of c-myc transcripts has been observed in resting B or T cells after mitogen stimulation (20) and in quiescent BALB/c 3T3 fibroblast cells following exposure to serum or platelet-derived growth factor (20, 21) . This increase occurs early in the Go/G1 period of the cell cycle (20, 21) . In the present experiments, the WEHI 231 cultures were not synchronized prior to initiation of treatment; therefore, an obvious experiment is to determine whether this c-myc activation can occur within cells at any stage of the cell cycle.
The results of our experiments indicate that c-myc gene expression is subject to stringent negative as well as positive regulation. Such tight regulation is unusual and suggests an important role for c-myc in cell proliferation. Though it is most likely that increased transcription is responsible for the enhanced levels of c-myc mRNA, the possibility of altered processing has not been eliminated. For the decrease in cmyc mRNA levels, inhibition of mRNA production alone is probably not sufficient to explain the dramatic decline. Thus, we propose that a specific turnover mechanism may play a role. Between 2 and 4 hr following initiation of anti-sIg treatment, the drop in c-myc mRNA levels was by a factor of 25-50. From these values an approximate half-life of between 20 and 30 min can be derived. The degradation appears specific for c-myc mRNA since other messages were not significantly affected by anti-sIg treatment. In addition, the decrease is much more dramatic than that observed for the decline in c-myc RNA levels following mitogen stimulation of B or T cells or during terminal differentiation of F9 teratocarcinoma cells (20, 21) . Thus, although synthesis of cmyc mRNA may be inhibited between 2 and 4 hr of anti-sIg treatment, the data suggest that during this period the production of some factor involved in c-myc mRNA degradation predominates. This could be new synthesis of a protein factor (or activation of a pre-existing factor) that recognizes some specific sequence within the c-myc mRNA and focuses a ribonuclease activity. Alternatively, a ribonuclease itself may be synthesized that specifically recognizes some structural feature of the c-myc mRNA (26) . Similar half-lives have been measured for some of the histone mRNAs (27) that are controlled at multiple levels, including transcription and RNA turnover (27) .
Cells treated with anti-Ig for 24 hr are severely inhibited in their ability to synthesize proteins. In contrast, they appear to have virtually a full complement of messages, as judged by translation in a cell-free system. Thus, these cells are apparently under some form of translational control. The site of this regulation remains to be determined. Some proteins appear to be more resistant to this inhibition. One band of =35 kDa may be of interest, since a nuclear glycoprotein of similar size (35 kDa) was detectable specifically in resting B cells (28 
